Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 1 | — | — | — | 1 |
Lymphoma | D008223 | — | C85.9 | — | 1 | — | — | — | 1 |
Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | — | 1 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 1 | — | — | — | 1 |
Drug common name | Mitoguazone |
INN | mitoguazone |
Description | Mitoguazone is a hydrazone obtained by formal condensation of the two carbonyl groups of methylglyoxal with the primary amino groups of two molecules of aminoguanidine. It has a role as an antineoplastic agent, an apoptosis inducer and an EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor. It is a hydrazone and a member of guanidines. It is functionally related to a methylglyoxal and an aminoguanidine. It is a conjugate base of a mitoguazone(2+). |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(/C=N/NC(=N)N)=N\NC(=N)N |
PDB | — |
CAS-ID | 459-86-9 |
RxCUI | — |
ChEMBL ID | CHEMBL216913 |
ChEBI ID | 43996 |
PubChem CID | 5351154 |
DrugBank | — |
UNII ID | OD5Q0L447W (ChemIDplus, GSRS) |